SAN DIEGO, Oct. 3, 2017 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a leading commercial provider of liquid biopsy
tests designed to provide physicians with clinically actionable
information to improve the outcomes of cancer patients, announces
that it has entered into a Promotion and Marketing Agreement with
Miraca Life Sciences, Inc. (MLS) to market Biocept's Target
Selector™ liquid biopsy tests and services to community-based
oncologists and hematologists in specified sales territories in
the United States. Based on the
Agreement, MLS' sales professionals will promote Biocept's Target
Selector testing to both their existing and new clinician clients
in the specified sales territories. Biocept will perform all tests
in its CLIA-certified laboratory in San
Diego.
Biocept's Target Selector platform offers a best-in-class
solution for the community oncologist, with tests that are focused
on NCCN-actionable biomarkers, offer market-leading sensitivity,
and are accessible to patients through most health plans.
"By working with Biocept, MLS can offer our clinician clients an
advanced liquid biopsy solution," said Tom
Zaves, Senior Vice President of Strategic Operations for
MLS. "This addition enables Miraca to provide comprehensive genomic
profiling through both tissue and liquid biopsy, which we believe
supplies better information for the referring oncologist. This can
lead to more effective treatment selection and ultimately result in
better outcomes for patients with cancer."
"A major objective for Biocept is to increase the adoption of
our Target Selector testing services globally, and we believe that
this agreement will enable us to expand our service offering in the
U.S. market with the help of Miraca Life Sciences, a leading
diagnostics laboratory and service provider," said Biocept's
President and Chief Executive Officer Michael Nall. "An important aspect of this
relationship is the synergy that we expect to generate between MLS'
current lab service offering and our liquid biopsy platform. We
look forward to working with the MLS team to establish a successful
relationship in the initial sales territories under our agreement,
with the opportunity for expansion across the U.S."
About Miraca Life Sciences
Miraca Life Sciences provides proven high-quality anatomic and
clinical pathology services, focusing on the fields of
gastroenterology, dermatology, hematology, urology, and breast
health. Miraca Life Sciences' team of more than 80 distinguished
subspecialist pathologists utilizes state-of-the-art laboratories
to serve more than 5,500 patients every day. Miraca Life Sciences'
difference is based on consensus-based medicine (including
comprehensive sub-subspecialization, unified terminology and
criteria, daily consensus conferences, disease-focused projects,
and extensive educational activities), rigorous quality assurance,
active clinical research, innovation in testing, technological
advancements, and health IT consulting services for clinician
clients. Headquartered in Irving,
Texas, Miraca Life Sciences is a subsidiary of Miraca
Holdings Inc., one of Japan's
largest clinical diagnostics and laboratory testing service
providers. Avista Capital Partners has agreed to acquire Miraca
Life Sciences from Miraca Holdings Inc., and the transaction is
expected to close in the fourth quarter of 2017. For more
information, visit www.MiracaLifeSciences.com.
About Biocept
Biocept, Inc. is a molecular diagnostics
company with commercialized assays for lung, breast, gastric,
colorectal and prostate cancers, and melanoma. The Company
leverages its proprietary liquid biopsy technology to provide
physicians with clinically actionable information for treating and
monitoring patients diagnosed with cancer. Biocept's patented
Target Selector™ liquid biopsy technology platform captures and
analyzes tumor-associated molecular markers in both circulating
tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With
thousands of tests performed, the platform has demonstrated the
ability to identify cancer mutations and alterations to inform
physicians about a patient's disease and therapeutic options. For
additional information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This
news release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
be correct. Forward-looking statements are generally identifiable
by the use of words like "may," "will," "should," "could,"
"expect," "anticipate," "estimate," "believe," "intend" or
"project," or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this news release are not strictly historical,
including, without limitation, statements as to our ability to
identify specific clinical conditions or improve the outcomes of
cancer patients, our ability to increase the adoption of our Target
Selector testing services in the U.S. and globally, our ability to
create synergies between MLS's current lab service offering and our
liquid biopsy platform, our ability to expand the number of sales
territories covered by the agreement with MLS, and the financial
impact of new contracts, such statements are forward-looking, and
are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. The reader is cautioned
not to put undue reliance on these forward-looking statements, as
these statements are subject to numerous risk factors as set forth
in our Securities and Exchange Commission (SEC) filings. The
effects of such risks and uncertainties could cause actual results
to differ materially from the forward-looking statements contained
in this news release. We do not plan to update any such
forward-looking statements and expressly disclaim any duty to
update the information contained in this press release except as
required by law. Readers are advised to review our filings with the
SEC at www.sec.gov
View original content with
multimedia:http://www.prnewswire.com/news-releases/biocept-and-miraca-life-sciences-enter-into-marketing-agreement-to-expand-target-selector-testing-in-the-united-states-300529618.html
SOURCE Biocept, Inc.